Abstract:Background: Esophageal cancer is one of the most common malignant tumors in the world. With currently available therapies, only 20% ~30% patients can survive this disease for more than 5 years. Although TRAIL, a natural ligand for death receptors that can induce the apoptosis of cancer cells, has been explored as a therapeutic agent for cancers, it has been reported that many cancer cells are resistant to TRAIL, limiting the potential clinical use of TRAIL as a cancer therapy. Meanwhile, Periplocin (CPP), a natural compound from dry root of Periploca sepium Bge, has been studied for its anti-cancer activity. It is not clear if CPP and TRAIL can have activity on esophageal squamous cell carcinoma (ESCC) cells, or if the combination of these two agents can have synergistic activity. Methods: We used MTS assay, flow cytometry and TUNEL assay to detect the effects of CPP alone and in combination with TRAIL in ESCC cells. The mechanism of CPP enhances the activity of TRAIL was analyzed by western blot, dual luciferase reporter gene assay and ChIP assay and so on. The anti-tumor effects and the potential toxic side effects of CPP alone and in combination with TRAIL were also evaluated in vivo. Findings: In our studies, we found that CPP alone and in combination with TRAIL could inhibit the proliferation ESCC cells and induce apoptosis. For the first time, we identified FoxP3 as a key transcriptional repressor for both DR4 and DR5. By down-regulating FoxP3, CPP increases the expression of DR4/DR5 and renders ESCC cells much more sensitive to TRAIL. We also showed that CPP reduced the expression of Survivin by inhibiting the activity of Wnt/β-catenin pathway. All these contribute to synergistic in vitro and in vivo activity of CPP and TRAIL on ESCC cells. Interpretation: Our data suggests that CPP and TRAIL can be further explored as potential therapeutic approach for esophageal cancer. Funding: This project was supported by the Natural Science Foundation of China (Grant No. 81673642, 81772550). Conflict of Interest: The authors declared no conflict of interest. Ethical Approval: All animal experiments were approved by the Animal Care Committee of the Fourth Hospital of Hebei Medical University.

Thapsigargin sensitizes human esophageal cancer to TRAIL-induced apoptosis via AMPK activation

Periplocin Sensitizes Human Esophageal Squamous Cell Carcinoma to Trail-Induced Apoptosis Via Upregulating Death Receptors and Inhibiting the Wnt/β-Catenin Pathway

Trichostatin A Potentiates TRAIL-induced Antitumor Effects Via Inhibition of ERK/FOXM1 Pathway in Gastric Cancer

Ecliptasaponin A induces apoptosis through the activation of ASK1/JNK pathway and autophagy in human lung cancer cells.

Cisplatin-dependent upregulation of death receptors 4 and 5 augments induction of apoptosis by TNF-related apoptosis-inducing ligand against esophageal squamous cell carcinoma

Combination of the Natural Compound Periplocin and TRAIL Induce Esophageal Squamous Cell Carcinoma Apoptosis in Vitro and in Vivo: Implication in Anticancer Therapy.

TRAIL promotes epithelial-to-mesenchymal transition by inducing PD-L1 expression in esophageal squamous cell carcinomas

Resveratrol-induced Apoptosis is Enhanced by Inhibition of Autophagy in Esophageal Squamous Cell Carcinoma

Thapsigargin Potentiates TRAIL-induced Apoptosis in Giant Cell Tumor of Bone

Apatinib induces endoplasmic reticulum stress-mediated apoptosis and autophagy and potentiates cell sensitivity to paclitaxel via the IRE-1α–AKT–mTOR pathway in esophageal squamous cell carcinoma

EGFR Inhibitors Sensitize Non-Small Cell Lung Cancer Cells to TRAIL-induced Apoptosis

Celastrol Inhibited Human Esophageal Cancer by Activating DR5-Dependent Extrinsic and Noxa/Bim-Dependent Intrinsic Apoptosis

Proteasome inhibitor MG132 inhibits the proliferation and promotes the cisplatin-induced apoptosis of human esophageal squamous cell carcinoma cells

Bortezomib Sensitizes Human Esophageal Squamous Cell Carcinoma Cells to TRAIL–Mediated Apoptosis via Activation of Both Extrinsic and Intrinsic Apoptosis Pathways

Downregulation of XIAP Expression Induces Apoptosis and Enhances Chemotherapeutic Sensitivity in Human Gastric Cancer Cells

CCN1 sensitizes esophageal cancer cells to TRAIL-mediated apoptosis

Retracted: Dasatinib Promotes TRAIL‐mediated Apoptosis by Upregulating CHOP‐dependent Death Receptor 5 in Gastric Cancer

Supplementary Tables from Neddylation Inhibition Activates the Extrinsic Apoptosis Pathway Through ATF4–CHOP–DR5 Axis in Human Esophageal Cancer Cells

Paclitaxel Sensitizes Gastric Cancer Cells to TRAIL-induced Apoptosis

Simultaneous targeting PI3K and PERK pathways promotes cell death and improves the clinical prognosis in esophageal squamous carcinoma.

Esophageal Cancer Cells Convert the Death Signal from TRAIL into a Stimulus for Survival During Acid/bile Exposure.